Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Mary Yurko

Dermatology Grand Rapids, MI Medical Doctor

NPI 1124012992 CMS profile 322514

833 Michigan St Ne, Suite 102, Grand Rapids, MI 49503

Open in the dashboard

General payments

$3,019

162 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Mary Yurko of Grand Rapids, MI is reported in the CMS Open Payments database as having received $3,019 across 162 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $18 1
2020 General $1,189 66
2019 General $1,812 95

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary Yurko
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Mary Yurko were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Mary Yurko Dermatology median Middle half National median
2019 $1,812 $454 $129–$1,240 $163
2020 $1,189 $235 $81–$756 $114
2021 $0 $377 $108–$1,108 $132
2022 $0 $514 $143–$1,391 $149
2023 $18 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $997 47 payments
  2. Novartis Pharmaceuticals Corporation $577 33 payments
  3. Amgen Inc. $320 21 payments
  4. Ortho Dermatologics, a division of Bausch Health US, LLC $285 10 payments
  5. Pfizer Inc. $205 17 payments
  6. Genzyme Corporation $187 5 payments
  7. Regeneron Healthcare Solutions, Inc. $75 4 payments
  8. Janssen Biotech, Inc. $62 5 payments
  9. UCB, Inc. $48 2 payments
  10. Almirall LLC $39 3 payments
  11. Other $227 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,019 162 payments
Products named General payments · program years 2019–2023
  1. HUMIRA $881 42 payments
  2. SKYRIZI $609 32 payments
  3. COSENTYX Dermatology $332 19 payments
  4. COSENTYX Immunology $226 13 payments
  5. EUCRISA $205 17 payments
  6. DUPIXENT $131 2 payments
  7. Enbrel Inflammation $126 9 payments
  8. ALTRENO $118 3 payments
  9. SILIQ $115 2 payments
  10. Enbrel Inflammation $114 8 payments
  11. Other $803 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

162 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record